Novartis AG said an experimental medicine helped patients with an autoimmune disease in late-stage studies, offering a boost ...

The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

In the final overall survival analysis, researchers pitted Lu-177-PSMA-617 (Pluvicto) against an ARPI in the second-line ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a ...

The Swiss government met with executives of Roche Holding AG and Novartis AG to discuss the pharmaceutical industry’s ...

Novartis has been evaluating a bid for Avidity, which had a market value of about $5.8bn at market close on Wednesday, and ...

Swiss ministers have met with senior executives of pharmaceutical companies Roche and Novartis to discuss the outlook for the ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

Avidity Biosciences (NASDAQ:RNA) stock surged 18% Wednesday after the Financial Times reported that Swiss pharmaceutical ...

And if you're looking for top dividend-paying companies to put your money in right now, let's consider two excellent ...

The state of Maine is being sued by a pharmaceutical company over its discount drug program. Novartis, a New Jersey-based company, is seeking to end Maine’s regulation of the 340B Drug Pricing Program ...